Celgene Corporation

Abraxis Bioscience, LLC

Daniel W Pierce

Neil P Desai

Lilly L Wong

Willard Foss

Viktor Peykov

Hon-Wah Man

Matthew David Alexander

Joshua Hansen

Antonia Lopez-Girona

Timothy S Kercher

Matthew Daniel Correa

Mark A Nagy

Brandon Wade Whitefield

Brian Edwin Cathers

Nanfei Zou

Paula Alessandra Tavares-Greco

Xiaoling Lu

Courtney G Havens

Gerald D Artman, Iii

Joseph R Piccotti

James Carmichael

Rama Krishna Narla

Michael Pourdehnad

Kyle MacBeth

Gang Lu

Yu Pu

Tonia J Buchholz

Soraya Carrancio

Jinhong Fan

Paula A Tavares-greco

Tsun-Wen Yao

Gordon L Bray

Sheena Yao

Naijun Wu

Rajan Gupta

Peng Wang

Gerald D Iii Artman

Emily Pace

Provided herein are methods of treating, preventing, managing, and/or ameliorating hypotension related to administration of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a cancer patient, wherein the methods comprise administering a combination comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof and a glucocorticoid receptor agonist, an interleukin-1 receptor antagonist, or an interleukin-1β blocker.

Combination therapy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

The present invention provides methods of assessing suitability of a pharmaceutical composition for medical use. The pharmaceutical composition comprises nanoparticles comprising rapamycin coated with albumin and a non-nanoparticle portion comprising albumin and rapamycin.

Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug

Provided herein is are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof and a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3ε (CD3) provided herein, in treating, preventing or managing multiple myeloma.

Antiproliferative compounds and bispecific antibody against BCMA and CD3 for combined use

Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.

Antiproliferative compounds and methods of use thereof

Provided herein is are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof and a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3&#x3b5; (CD3) provided herein, in treating, preventing or managing multiple myeloma.

The present invention provides methods of assessing suitability of a pharmaceutical composition for medical use. The pharmaceutical composition comprises nanoparticles comprising paclitaxel coated with albumin and a non-nanoparticle portion comprising albumin and paclitaxel.

Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel

Growing community of inventors

Belmont, CA, United States of America

Daniel W Pierce